

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EC Healthcare

醫思健康

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2138)

INSIDE INFORMATION SALES VOLUME UPDATE

This announcement is made by EC Healthcare (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

SALES VOLUME FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2022

The Board wishes to further inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the latest assessment by the Board with reference to the preliminary unaudited management accounts of the Group for the six months ended 30 September 2022 (the “**Reporting Period**”) currently available, the Group’s performance on sales volume (being the total sales volume generated from contracted sales entered into, and all products and services offered by the Group, the “**Sales Volume**”) is summarized as below:

Six months ended	Year-on-year growth
30 September 2022	(Compared with same period in 2021)
Overall Sales Volume	Increase by 17%+
Sales Volume of medical services	Increase by 30%+
Sales Volume of aesthetic medical and beauty and wellness services in Hong Kong and Macau	Decrease by 9%-
Sales Volume of aesthetic medical and beauty and wellness services in Mainland China	Decrease by 15%-
Sales Volume of other services	Increase by 95%+

Note: (+) refers to no less than, (-) refers to no more than

The Group expects to record:

- (i) overall Sales Volume of no less than HK\$1,800 million for the Reporting Period, representing an increase of no less than 17% as compared with the same period last year;
- (ii) an increase in Sales Volume of medical services offered by the Group of no less than 30% for the Reporting Period as compared with the same period last year;
- (iii) a decrease in Sales Volume of aesthetic medical and beauty and wellness services located in Hong Kong and Macau offered by the Group of no more than 9% for the Reporting Period as compared with the same period last year;
- (iv) a decrease in Sales Volume of aesthetic medical and beauty and wellness services located in Mainland China offered by the Group of no more than 15% for the Reporting Period as compared with the same period last year; and
- (v) an increase in Sales Volume of other services offered by the Group of no less than 95% for the Reporting Period as compared with the same period last year.

The Board wishes to remind Shareholders and potential investors that the above operational data are based on the unaudited management accounts of the Group which have not been reviewed or audited by the auditors of the Company. Sales performance during the Reporting Period may be affected by a series of factors, and the operational data disclosed in this announcement may not be able to reflect the overall performance of the Group for a complete Reporting Period.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
EC Healthcare
Raymond Siu
Company Secretary

Hong Kong, 17 October 2022

As at the date of this announcement, the executive Directors of the Company are Mr. Tang Chi Fai, Mr. Lu Lyn Wade Leslie, Mr. Lee Heung Wing, Ms. Wong Ka Ki Ada, and Mr. Wong Chi Cheung; the non-executive Director is Mr. Luk Kun Shing Ben; and the independent non-executive Directors are Mr. Ma Ching Nam, Mr. Look Andrew and Mr. Au Tsun.